Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Vet Pharmacol Ther ; 31(5): 415-22, 2008 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-19000260

RESUMEN

The purpose of the study was to assess the pharmacokinetics of liposome-encapsulated (DPPC-C) hydromorphone administered intravenously (IV) or subcutaneously (SC) to dogs. A total of eight healthy Beagles aged 12.13 +/- 1.2 months and weighing 11.72 +/- 1.10 kg were used. Dogs randomly received liposome encapsulated hydromorphone, 0.5 mg/kg IV (n = 6), 1.0 mg/kg (n = 6), 2.0 mg/kg (n = 6), or 3.0 mg/kg (n = 7) SC with a 14-28 day washout between trials. Blood was sampled at serial intervals after drug administration. Serum hydromorphone concentrations were measured using liquid chromatography with mass spectrometry. Serum concentrations of hydromorphone decreased rapidly after IV administration of the DPPC-C formulation (half-life = 0.52 h, volume of distribution = 12.47 L/kg, serum clearance = 128.97 mL/min/kg). The half-life of hydromorphone after SC administration of DPPC-C formulation at 1.0, 2.0, and 3.0 mg/kg was 5.22, 31.48, and 24.05 h, respectively. The maximum serum concentration normalized for dose (C(MAX)/D) ranged between 19.41-24.96 ng/mL occurring at 0.18-0.27 h. Serum hydromorphone concentrations fluctuated around 4.0 ng/mL from 6-72 h after 2.0 mg/kg and mean concentrations remained above 4 ng/mL for 96 h after 3.0 mg/kg DPPC-C hydromorphone. Liposome-encapsulated hydromorphone (DPPC-C) administered SC to healthy dogs provided a sustained duration of serum hydromorphone concentrations.


Asunto(s)
Analgésicos Opioides/administración & dosificación , Analgésicos Opioides/farmacocinética , Hidromorfona/administración & dosificación , Hidromorfona/farmacocinética , Analgésicos Opioides/sangre , Animales , Área Bajo la Curva , Química Farmacéutica , Perros , Semivida , Hidromorfona/sangre , Inyecciones Subcutáneas , Liposomas , Masculino , Tasa de Depuración Metabólica
2.
J Craniofac Genet Dev Biol ; 5(2): 121-45, 1985.
Artículo en Inglés | MEDLINE | ID: mdl-4019727

RESUMEN

A new recessive lethal mutation in mice that produces the otocephaly defect is described. The mutation, provisionally named oto is located on chromosome 1, within, or just outside of, a previously existing inversion, In(1)1Rk, and was probably induced by X-irradiation. The penetrance of oto is nearly complete on C57BL strain backgrounds but is reduced to a variable extent on other backgrounds. The previously reported liability to spontaneous otocephaly in the C57BL strains appears to increase the penetrance of oto. Studies of the sequences of developmental changes (conducted primarily by scanning electron microscopy) and of the range of defects indicate that a primary deficiency involving the anterior aspect of the embryonic disc occurs in affected individuals. An hypothesis related to deficiencies in mesodermal populations is presented as the basis for the craniofacial and brain defects observed.


Asunto(s)
Encéfalo/anomalías , Aberraciones Cromosómicas/veterinaria , Inversión Cromosómica , Disostosis Craneofacial/veterinaria , Genes Letales , Ratones Mutantes/genética , Enfermedades de los Roedores/genética , Animales , Encéfalo/embriología , Aberraciones Cromosómicas/embriología , Aberraciones Cromosómicas/genética , Trastornos de los Cromosomas , Disostosis Craneofacial/embriología , Disostosis Craneofacial/genética , Oído/anomalías , Embrión de Mamíferos/ultraestructura , Femenino , Masculino , Mesodermo/ultraestructura , Ratones , Ratones Mutantes/embriología , Enfermedades de los Roedores/embriología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...